BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category 

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue. 

Sheridan is being recognized for his role in transforming Nutriband from an early-stage startup into a U.S.-listed life sciences company focused on transdermal drug delivery and abuse-deterrent technologies. The company’s lead product, AVERSA™, is designed to prevent the misuse and abuse of opioid patches—addressing a critical gap in pain management. 

Finalists in the EY program will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, to be awarded at a gala event in November. 

To view the full article, visit https://ibn.fm/FNBFI 

About Nutriband Inc. 

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com. 

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN